Neotri MR is commonly used to provide specialized symptomatic and supportive care for adults with chronic heart conditions. Its role is to help manage the symptom burden that arises from insufficient oxygen supply to the heart muscle. Its function is established as a second-line, add-on therapy.

The medication is generally applied for the long-term, stable management of Angina Pectoris, a condition characterized by predictable, recurring chest discomfort or pressure. It helps address the core manifestation of Myocardial Ischemia and may assist with managing the overall frequency of angina episodes, and contribute to easing the patient's need for symptomatic rescue medications.

Its primary use is for individuals with stable angina pectoris whose symptoms remain inadequately controlled by, or who are intolerant to, conventional first-line therapies. This supportive relief may assist with maintaining functional stability, and may help patients better cope with their condition.

“The therapeutic aim is to provide symptomatic relief and support general comfort during periods of heightened physical activity.”

Quick Fact: Focus on Symptomatic Management of Exercise-Induced Discomfort

---

Support for Physical Function and Symptom Tolerance

Neotri MR supports patients by addressing the functional limitations associated with their condition, particularly the reduced exercise capacity and the swift onset of symptoms during physical activity. This action supports the patient during symptomatic periods and may contribute to improved comfort when performing routine tasks.

Regulatory References

1. Summary of Product Characteristics from the Health Products Regulatory Authority

Who can and cannot use Neotri MR?

The official regulatory profile defines eligibility for Neotri MR, restricting its use primarily to the adult population indicated for stable angina pectoris. The medicine is classified as contraindicated for several specific population groups, as defined in regulatory labeling.

Absolute Contraindications The medicine must not be used by patients who have:

• Known hypersensitivity to the active substance or to any of the product’s excipients.
• Parkinson's disease, parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders.
• Severe renal impairment, defined as a creatinine clearance less than 30 mL/min.

Conditional and Not Recommended Use Eligibility is further restricted by age and organ function:

• Pediatric Population: Use in children and adolescents aged below 18 years is not recommended because safety and efficacy data have not been established.
• Renal Function: Caution is mandatory when prescribing to patients with moderate renal impairment (creatinine clearance between 30 and 60 mL/min).
• Older Adults: Caution is also necessary for patients older than 75 years due to the potential for increased exposure.
• Reproductive Status: Use is not recommended during breastfeeding, and regulatory documents indicate it is preferable to avoid use during pregnancy.

Neotri MR Interactions with other medicines and products

The official regulatory profile for Neotri MR (Trimetazidine dihydrochloride) is highly specific and details limited constraints regarding co-administration. The interaction structure is defined by both a pharmacodynamic risk and a population-specific pharmacokinetic constraint.

Documented Drug-Drug Interaction

The primary documented drug-drug interaction is pharmacodynamic in nature. Co-administration with L-Dopa (Levodopa) carries an official warning due to the potential for an additive effect. This documented interaction may increase the risk of developing or worsening Parkinsonian symptoms (e.g., tremor, rigidity, akinesia). This specific combination is classified as a use-with-caution interaction in official regulatory documents.

Pharmacokinetic Context and Restrictions

Official regulatory texts do not document clinically significant pharmacokinetic interactions involving the CYP450 enzyme system or major drug transporters. The drug is largely cleared unchanged by the kidneys, minimizing typical metabolic interaction pathways. Furthermore, no specific interactions with food, alcohol, or herbal products are documented, and no mandatory timing requirements or dose separation rules are specified.

Population-Specific Constraint

A key constraint relates to patient renal status. Due to reduced drug clearance, patients with moderate renal impairment must be managed under a restriction that requires a formal reduction in the total daily administered dose. This procedural constraint, required by regulatory labels, addresses the heightened risk of drug accumulation and increased systemic exposure.

How Neotri MR Works

The mechanism of Trimetazidine dihydrochloride is focused on optimizing myocardial energy metabolism, resulting in the modulation of cellular processes that is independent of heart rate or blood pressure changes.

Inhibition of Long-Chain Fatty Acid Oxidation (LC-FAO)

The drug functions as a metabolic modulator by selectively inhibiting the mitochondrial enzyme LC 3-KAT (Long-Chain 3-Ketoacyl-CoA Thiolase). This enzyme is required for the final steps of fatty acid oxidation (FAO), the heart cell's primary energy source. This inhibition directly initiates a compensatory metabolic shift, causing the heart to increase its reliance on glucose oxidation, a fundamentally more oxygen-efficient method of producing ATP (cellular energy).

️ Enhancing Oxygen Efficiency and Cytoprotection

This metabolic re-routing ensures a sustained and efficient ATP supply during conditions of reduced oxygen availability. The mechanism results in the preservation of function of energy-dependent ion pumps on the cell membrane, preventing the toxic accumulation of ions like sodium and calcium inside the myocardial cell. This action sustains the integrity of the cell membrane and supports normal cellular contractile function, thereby providing targeted physiological modulation.

How to Use Neotri MR: Official Administration Guidelines

Neotri MR (Trimetazidine dihydrochloride 35 mg) is a Modified-Release (MR) tablet taken via the oral route. The standard usage principles are designed to ensure consistent administration and proper systemic exposure.

---

Administration Scope

Feature	Official Instruction
Route of administration:	Oral administration.
Dosing schedule (Adult):	One 35 mg tablet per dose.
Timing in relation to meals:	Must be taken with meals (during food intake).
Frequency:	Twice daily (morning and evening).
Missed-dose rules:	Resume treatment normally with the next dose; do not double the dose to compensate.
Special procedural conditions:	Tablets must be swallowed whole and not crushed or split.

---

Population-Specific Instructions

Official labeling requires dosage modification for certain patient groups, particularly those with reduced kidney function:

• Moderate Renal Impairment (Creatinine Clearance 30–60 mL/min): The dose must be reduced to one 35 mg tablet once daily, taken in the morning during breakfast.
• Elderly Patients: Caution is advised due to age-related decrease in kidney function, and the reduced once-daily regimen is recommended if moderate renal impairment is present.
• Pediatric Population (Below 18 years): Use is not recommended as safety and efficacy have not been established.

Treatment benefit must be formally assessed after three months of use, and the medication should be discontinued if no response is observed.

Research Evidence / Overview of Studies for Neotri MR

Evidence for Use in Stable Angina Pectoris

Neotri MR was studied for the long-term management of stable angina pectoris, a condition characterized by functional limitations and periods of heightened symptom activity. The core evidence for the approved indication includes numerous Randomized Controlled Trials (RCTs) and meta-analyses that consolidate findings from many different studies. These trials primarily focused on adults with existing stable angina whose symptoms were not fully managed by, or who had difficulty tolerating, conventional first-line heart medications.

Research examined outcomes related to physical discomfort and the body's physiological strain during activity. Studies monitored the frequency of patient-reported angina attacks per week and the rate of short-acting nitrate use. The findings describe patterns observed where adding Neotri MR to existing treatment showed differences in the frequency of angina episodes and the rate of rescue medication use compared to groups receiving a placebo. The evidence for these symptomatic and functional endpoints is broadly classified as consistent (High level) across the synthesized research.

How Neotri MR Was Studied Against Placebo and Standard Treatments

Most studies focused on assessing the medicine as an add-on therapy in a double-blind setting, meaning it was observed in patients who were already taking standard antianginal drugs. This design helps contextualize how patients reported their experience when Neotri MR was associated with their total medication plan.

Evidence for Use in Coronary Artery Disease After Intervention

Studies also monitored Neotri MR's use as an adjunct therapy for patients who have undergone revascularization procedures, such as stenting (PCI). These research programs primarily examined whether the medicine was associated with changes in events such as cardiac mortality and Major Adverse Cardiac Events (MACE) over several years of follow-up.

The largest dedicated trials did not show patterns of difference compared to placebo regarding the composite primary endpoint of MACE and mortality. This evidence is classified as having Low to Moderate certainty for these particular long-term outcomes.

What is Still Uncertain About the Research Evidence

One key area of ongoing uncertainty is the long-term impact on hard cardiovascular outcomes (like reducing the rate of heart attacks or overall mortality), where certainty remains low. Furthermore, the comparative evidence is lacking in large-scale studies that directly compare Neotri MR against all other standard antianginal medications head-to-head. Findings and results apply only to the populations studied in the clinical programs reviewed by regulators.

Common questions about Neotri MR (FAQ)

Q: What is Neotri MR used for?

Neotri MR (Modified Release) is generally used to treat angina pectoris (chest pain caused by reduced blood flow to the heart) in patients whose symptoms are not adequately controlled by or who are intolerant to first-line anti-anginal therapies. It may also be used as an add-on therapy for managing vertigo (a sensation of spinning or dizziness) associated with Meniere’s disease, and for treating tinnitus (ringing in the ears) when it is linked to inner ear issues (cochlear disorders).

---

Q: How does Neotri MR work?

Neotri MR contains the active ingredient trimetazidine. It belongs to a class of medicines known as metabolic agents. Trimetazidine works by protecting the heart cells from the effects of ischemia (reduced oxygen supply) and improving the way heart muscle cells use energy. This action helps to optimize the function of the heart muscle, especially during periods of reduced blood flow, which in turn helps to reduce the frequency of angina attacks and improve exercise tolerance.

---

Q: What is the typical dosage for Neotri MR?

Neotri MR is an oral medication, typically taken as a single tablet twice a day, once in the morning and once in the evening, usually with meals. The exact dosage and duration of treatment will be determined by a healthcare professional based on the individual's medical condition and response to the medicine. It is crucial to follow the prescribed regimen exactly and not to chew, crush, or divide the tablets, as this can affect the modified-release properties.

---

Q: Who should not take Neotri MR?

Neotri MR is contraindicated (should not be taken) by individuals who have:

• Hypersensitivity (allergy) to trimetazidine or any of the other ingredients.
• Parkinson's disease or symptoms of Parkinson's disease, such as tremors, rigidity, or difficulty walking.
• Severe kidney problems (severe renal impairment).
• Restless legs syndrome or other related movement disorders.

Always inform your doctor about your full medical history and all medications you are currently taking before starting Neotri MR.

---

Q: Can Neotri MR cause dizziness or affect driving?

Yes, Neotri MR may cause side effects such as dizziness, drowsiness, or visual disturbances in some people. These effects could impair the ability to drive or operate machinery. Patients should be aware of how they react to the medication before engaging in activities that require alertness. If you experience these symptoms, avoid driving and consult your healthcare professional.

---

Q: Is Neotri MR the same as a blood pressure medicine?

No, while Neotri MR is used to treat a heart condition (angina), it is not primarily a blood pressure medicine. It works by improving the metabolism of the heart cells, rather than directly lowering blood pressure or affecting heart rate in the same way as many common blood pressure medications. It does not replace standard treatments for high blood pressure or other heart conditions. Your doctor may prescribe it alongside other medications.

How to Store and Dispose of Neotri MR

The storage and disposal of Neotri MR (Trimetazidine dihydrochloride modified-release tablets) must comply with official regulatory labeling to ensure product stability and environmental safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at a temperature not exceeding 30 C
Protection	Must be protected from light and moisture
Packaging	Keep in the original outer carton and blister packaging
Safety	Must be kept out of the reach and sight of children

Disposal Instructions

Unused or expired Neotri MR must not be disposed of via wastewater or household waste. Disposal must be done in accordance with local regulations, and patients are advised to consult a pharmacist for guidance on returning the medicine for proper pharmaceutical waste handling.